A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Starting soon · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Long COVID

In brief

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.

Key facts

Study ID: NCT06974084
Run by: HealthBio, Inc.
People needed: 252
Starts: 2026-07-15
Expected to finish: 2027-05-01
Last updated by the study team: 2026-06-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

An individual who meets any of the following criteria will be excluded from participation in this study:
Participation in another therapeutic clinical trial in the past 2 months.
History of allergy or anaphylaxis or allergic reaction to any component of atorvastatin and/or maraviroc.
Uncontrolled hypothyroidism as defined as thyroid-stimulating hormone (TSH) and/or free thyroxine (FT4) values outside the local laboratory reference range at screening, or a change in thyroid hormone replacement dose within 6 weeks prior to screening.
Pre-COVID history of autoimmune conditions, migraines, neuropathy, inflammatory bowel disease (IBD), obsessive-compulsive disorder (OCD), or fatigue duration for ≥5 years, EBV infection, Lyme disease, fibromyalgia, arthritis, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD G3a or greater), chronic heart failure (CHF), arrhythmias, bleeding disorders, and anticoagulation therapy.
Presence of other conditions or differential diagnosis that better explains the symptoms of the patient than the suspected long COVID, in the opinion of the investigator.
Hepatic impairment, defined as Child-Pugh Score 7-9 (Class B) or greater.
Active/acute infectious diseases like tuberculosis, human immunodeficiency virus infection (HIV), cytomegalovirus (CMV), (vector based) Lyme, EBV, hepatitis B virus (HBV), hepatitis C virus (HCV).
Ongoing immunosuppressive therapy, such as cyclosporine A (CsA).
Use of statins within 6 months of randomization.
Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir, or lipid-modifying doses (>1 gram/day) of niacin.
AST:ALT ratio>1.5
Elevations in IL-8 (>21 (pg/ml) and or IL-13 (>6.1 pg/ml) (centrally assessed with IncellKINE panel).
Pregnant or breastfeeding
History of substance use disorder (including alcohol use disorder or cannabis use disorder per DSM-5 criteria) within 3 months of enrollment, OR current hazardous alcohol use as defined by:
Self-reported consumption >14 drinks/week (males) or >7 drinks/week (females), OR
Binge drinking (≥5 drinks on one occasion for males, ≥4 for females) ≥1 time per week, OR
Clinical judgment that alcohol use would interfere with study compliance or safety
Subjects with risk factors for myocardial ischemia/infarction, including but not limited to those with a prior history of MI, stroke, unstable angina,
Any significant disease or disorder, which, in the opinion of the Investigator, may either put the participants at risk
Azole antifungals (ketoconazole or itraconazole are not allowed) or macrolide antibiotics (clarithromycin is not allowed)
History of use of maraviroc and/or atorvastatin for the off-label treatment of Long COVID.
Prohibited concomitant medications
Any statins within 6 months of randomization and between randomization and the participant's scheduled final visit
Other systemically administered drugs with significant immunosuppressive activity, such as azathioprine, tacrolimus, cyclosporine, methotrexate, or cytotoxic chemotherapy between randomization and the participant's scheduled final visit

Where it is running

University of Arizona — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.